Cost effectiveness of HMG-CoA reductase inhibition in Canada

Mason W. Russell, Daniel M. Huse, Jeffrey D. Miller, Dale Kraemer, Stuarts C. Hartz

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

OBJECTIVE: To assess the cost effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor therapy, particularly atorvastatin, in primary and secondary prevention of coronary artery disease (CAD) in Canada. METHODS: A Markov model was developed in which costs and effectiveness of atorvastatin were compared with those of other statins and with no drug therapy in primary and secondary prevention of CAD. PATIENTS: Cost effectiveness was assessed for cohorts of patients with risk profiles defined by CAD status, age, sex, pretreatment low density lipoprotein cholesterol level and presence of sentinel coronary risk factors. Coronary risk was estimated by using initial and subsequent event coronary risk equations from the Framingham Heart Study, and risk factors were estimated by using Canadian population survey data. Recent estimates of the costs of CAD-related medical care in Canada were used to assign costs to health states and acute coronary events. INTERVENTIONS: Interventions included atorvastatin 10 mg, simvastatin 10 mg, pravastatin 20 mg, fluvastatin 20 mg, lovastatin 20 mg and no pharmacological therapy. RESULTS: Incremental cost effectiveness ratios (CDN$/year of life gained) relative to no therapy were lowest for atorvastatin and highest for pravastatin across all risk profiles. Atorvastatin was less costly and more effective than lovastatin, pravastatin and simvastatin in primary and secondary prevention, and conferred additional health benefits at a reduced cost per year of life gained compared with fluvastatin. CONCLUSIONS: Atorvastatin was found to be the most cost effective statin in primary and secondary prevention of CAD.

Original languageEnglish (US)
Pages (from-to)9-16
Number of pages8
JournalCanadian Journal of Clinical Pharmacology
Volume8
Issue number1
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Coenzyme A
Cost-Benefit Analysis
Canada
Oxidoreductases
fluvastatin
Coronary Artery Disease
Primary Prevention
Secondary Prevention
Pravastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lovastatin
Simvastatin
Costs and Cost Analysis
Insurance Benefits
Health Care Costs
LDL Cholesterol
Atorvastatin Calcium
Therapeutics
Pharmacology
Drug Therapy

Keywords

  • Cost effectiveness analysis
  • HMG-CoA reductase inhibitor
  • Hypercholesterolemia
  • Lipid-regulating therapy

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

Russell, M. W., Huse, D. M., Miller, J. D., Kraemer, D., & Hartz, S. C. (2001). Cost effectiveness of HMG-CoA reductase inhibition in Canada. Canadian Journal of Clinical Pharmacology, 8(1), 9-16.

Cost effectiveness of HMG-CoA reductase inhibition in Canada. / Russell, Mason W.; Huse, Daniel M.; Miller, Jeffrey D.; Kraemer, Dale; Hartz, Stuarts C.

In: Canadian Journal of Clinical Pharmacology, Vol. 8, No. 1, 01.01.2001, p. 9-16.

Research output: Contribution to journalArticle

Russell, MW, Huse, DM, Miller, JD, Kraemer, D & Hartz, SC 2001, 'Cost effectiveness of HMG-CoA reductase inhibition in Canada', Canadian Journal of Clinical Pharmacology, vol. 8, no. 1, pp. 9-16.
Russell, Mason W. ; Huse, Daniel M. ; Miller, Jeffrey D. ; Kraemer, Dale ; Hartz, Stuarts C. / Cost effectiveness of HMG-CoA reductase inhibition in Canada. In: Canadian Journal of Clinical Pharmacology. 2001 ; Vol. 8, No. 1. pp. 9-16.
@article{95adc1b724e1422d989ee3989599be1f,
title = "Cost effectiveness of HMG-CoA reductase inhibition in Canada",
abstract = "OBJECTIVE: To assess the cost effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor therapy, particularly atorvastatin, in primary and secondary prevention of coronary artery disease (CAD) in Canada. METHODS: A Markov model was developed in which costs and effectiveness of atorvastatin were compared with those of other statins and with no drug therapy in primary and secondary prevention of CAD. PATIENTS: Cost effectiveness was assessed for cohorts of patients with risk profiles defined by CAD status, age, sex, pretreatment low density lipoprotein cholesterol level and presence of sentinel coronary risk factors. Coronary risk was estimated by using initial and subsequent event coronary risk equations from the Framingham Heart Study, and risk factors were estimated by using Canadian population survey data. Recent estimates of the costs of CAD-related medical care in Canada were used to assign costs to health states and acute coronary events. INTERVENTIONS: Interventions included atorvastatin 10 mg, simvastatin 10 mg, pravastatin 20 mg, fluvastatin 20 mg, lovastatin 20 mg and no pharmacological therapy. RESULTS: Incremental cost effectiveness ratios (CDN$/year of life gained) relative to no therapy were lowest for atorvastatin and highest for pravastatin across all risk profiles. Atorvastatin was less costly and more effective than lovastatin, pravastatin and simvastatin in primary and secondary prevention, and conferred additional health benefits at a reduced cost per year of life gained compared with fluvastatin. CONCLUSIONS: Atorvastatin was found to be the most cost effective statin in primary and secondary prevention of CAD.",
keywords = "Cost effectiveness analysis, HMG-CoA reductase inhibitor, Hypercholesterolemia, Lipid-regulating therapy",
author = "Russell, {Mason W.} and Huse, {Daniel M.} and Miller, {Jeffrey D.} and Dale Kraemer and Hartz, {Stuarts C.}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "8",
pages = "9--16",
journal = "Journal of Population Therapeutics and Clinical Pharmacology",
issn = "1710-6222",
publisher = "Pulsus Group Inc.",
number = "1",

}

TY - JOUR

T1 - Cost effectiveness of HMG-CoA reductase inhibition in Canada

AU - Russell, Mason W.

AU - Huse, Daniel M.

AU - Miller, Jeffrey D.

AU - Kraemer, Dale

AU - Hartz, Stuarts C.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - OBJECTIVE: To assess the cost effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor therapy, particularly atorvastatin, in primary and secondary prevention of coronary artery disease (CAD) in Canada. METHODS: A Markov model was developed in which costs and effectiveness of atorvastatin were compared with those of other statins and with no drug therapy in primary and secondary prevention of CAD. PATIENTS: Cost effectiveness was assessed for cohorts of patients with risk profiles defined by CAD status, age, sex, pretreatment low density lipoprotein cholesterol level and presence of sentinel coronary risk factors. Coronary risk was estimated by using initial and subsequent event coronary risk equations from the Framingham Heart Study, and risk factors were estimated by using Canadian population survey data. Recent estimates of the costs of CAD-related medical care in Canada were used to assign costs to health states and acute coronary events. INTERVENTIONS: Interventions included atorvastatin 10 mg, simvastatin 10 mg, pravastatin 20 mg, fluvastatin 20 mg, lovastatin 20 mg and no pharmacological therapy. RESULTS: Incremental cost effectiveness ratios (CDN$/year of life gained) relative to no therapy were lowest for atorvastatin and highest for pravastatin across all risk profiles. Atorvastatin was less costly and more effective than lovastatin, pravastatin and simvastatin in primary and secondary prevention, and conferred additional health benefits at a reduced cost per year of life gained compared with fluvastatin. CONCLUSIONS: Atorvastatin was found to be the most cost effective statin in primary and secondary prevention of CAD.

AB - OBJECTIVE: To assess the cost effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor therapy, particularly atorvastatin, in primary and secondary prevention of coronary artery disease (CAD) in Canada. METHODS: A Markov model was developed in which costs and effectiveness of atorvastatin were compared with those of other statins and with no drug therapy in primary and secondary prevention of CAD. PATIENTS: Cost effectiveness was assessed for cohorts of patients with risk profiles defined by CAD status, age, sex, pretreatment low density lipoprotein cholesterol level and presence of sentinel coronary risk factors. Coronary risk was estimated by using initial and subsequent event coronary risk equations from the Framingham Heart Study, and risk factors were estimated by using Canadian population survey data. Recent estimates of the costs of CAD-related medical care in Canada were used to assign costs to health states and acute coronary events. INTERVENTIONS: Interventions included atorvastatin 10 mg, simvastatin 10 mg, pravastatin 20 mg, fluvastatin 20 mg, lovastatin 20 mg and no pharmacological therapy. RESULTS: Incremental cost effectiveness ratios (CDN$/year of life gained) relative to no therapy were lowest for atorvastatin and highest for pravastatin across all risk profiles. Atorvastatin was less costly and more effective than lovastatin, pravastatin and simvastatin in primary and secondary prevention, and conferred additional health benefits at a reduced cost per year of life gained compared with fluvastatin. CONCLUSIONS: Atorvastatin was found to be the most cost effective statin in primary and secondary prevention of CAD.

KW - Cost effectiveness analysis

KW - HMG-CoA reductase inhibitor

KW - Hypercholesterolemia

KW - Lipid-regulating therapy

UR - http://www.scopus.com/inward/record.url?scp=0034767779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034767779&partnerID=8YFLogxK

M3 - Article

C2 - 11283756

AN - SCOPUS:0034767779

VL - 8

SP - 9

EP - 16

JO - Journal of Population Therapeutics and Clinical Pharmacology

JF - Journal of Population Therapeutics and Clinical Pharmacology

SN - 1710-6222

IS - 1

ER -